Tirzepatide

One-line placement: tirzepatide belongs to the incretin mimetics and was the first molecule to fold two receptors of this axis, GLP-1 and GIP, into one peptide chain.

What the research record holds so far:

• Structure: a synthetic peptide of 39 amino acids, shipped as a lyophilized powder that is dissolved with bacteriostatic water before laboratory use.
• Pharmacokinetics: a half-life of roughly five days, which is why study protocols worked with one administration per week.
• Evidence base: the SURMOUNT program is among the largest phase 3 series of recent years and tracks body weight, cardiovascular risk markers and metabolic adaptation across several years.
• Against mono-agonists: in research models, the effects on glucose control, satiety signals and fat metabolism come out more pronounced than with substances that engage the GLP-1 receptor alone.

On the mechanism: classical GLP-1 mimetics bind one receptor, tirzepatide binds two. The GIP component complements the GLP-1 pathway, and this interplay is the reason the molecule has shaped metabolic research so strongly. Stability and bioavailability are unusually well documented within the GLP-1/GIP class, making tirzepatide one of the most thoroughly characterized tools in the group. The sources below cover the three-year phase 3 data, a pooled tolerability analysis and a head-to-head comparison with semaglutide.

Across the SURMOUNT data, tirzepatide is rated as well tolerated overall; what is documented concerns mostly the gut and clusters at the start and during dose escalation.

• Stomach and bowel: nausea, vomiting, diarrhea and constipation lead the reports, especially where studies raised the dose quickly; slow escalation lowered the frequency markedly.
• Fluid balance: with appetite sharply reduced, participants eat and drink less, and the literature notes a higher risk of dehydration.
• Body composition: the weight lost in the studies includes a share of muscle alongside fat, as with other agonists of this class.
• Gallbladder and injection site: gallbladder complaints are described during rapid weight loss, plus mild local irritation.
• Very long use remains an open question: beyond the multi-year trials there are no robust data.

This summary is no substitute for medical advice.

• Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, 3-year data) - the three-year readout from the program's largest phase 3 trial.
• Tirzepatide compared with semaglutide (SURMOUNT-5 post-hoc analysis) - sets cardiovascular risk markers at 72 weeks against the mono-agonist semaglutide.
• Gastrointestinal tolerability and weight reduction (SURMOUNT-1 to -4) - pools the tolerability data of four SURMOUNT trials and relates them to weight outcomes.
• Tirzepatide after intensive lifestyle intervention (SURMOUNT-3) - looks at what happens when an intensive lifestyle program came first.